RT info:eu-repo/semantics/article
T1 Medium‐term changes in patients with epilepsy during the COVID‐19 pandemic
A1 González Martínez, Alicia
A1 Planchuelo Gómez, Álvaro
A1 Vieira Campos, Alba
A1 Martínez Dubarbie, Francisco
A1 Vivancos, José
A1 De Toledo Heras, María
K1 COVID-19
K1 Anxiety
K1 Epilepsy
K1 Pandemic
K1 Quality of life
K1 Sleep
AB Objectives: The novel coronavirus disease (COVID-19) pandemic has led to social distancing measures and impaired medical care of chronic neurological diseases, including epilepsy, which may have adversely affected well-being and quality of life of patients with epilepsy (PWE). The objective of this study is to evaluate the impact of the COVID-19 pandemic in the levels of anxiety, depression, somnolence, and quality of life using validated scales in PWE in real-life clinical practice.Materials & methods: Self-administered scales of anxiety disorders (GAD-7), depression (NDDI-E), somnolence (Epworth Sleepiness Scale; ESS), and quality of life (QOLIE-31-P) in PWE treated in a Refractory Epilepsy Unit were longitudinally analyzed. Data were collected before the beginning (December 2019 - March 2020) and during the COVID-19 pandemic (September 2020-January 2021).Results: 158 patients (85 from the first round and 73 from the second round) 45.0 ± 17.3 years of age, 43.2% women, epilepsy duration 23.0 ± 14.9 years, number of antiepileptic drugs 2.1 ± 1.4, completed the survey. Significant longitudinal reduction of QOLIE-31-P (from 58.9 ± 19.7 to 56.2 ± 16.2, p = .035) and GAD-7 scores (from 8.8 ± 6.2 to 8.3 ± 5.9, corrected p = .024) was identified. No statistically significant longitudinal changes in the number of seizures (from 0.9 ± 1.9 to 2.5 ± 6.2, p = .125) or NDDI-E scores (from 12.3 ± 4.3 to 13.4 ± 4.4, p = .065) were found. Significant longitudinal increase of ESS (from 4.9 ± 3.7 to 7.4 ± 4.9, p = .001) was found.Conclusions: During the COVID-19 pandemic, quality of life and anxiety levels were lower in PWE, and sleepiness levels were raised, without seizure change.
PB Wiley
SN 0001-6314
YR 2021
FD 2021
LK https://uvadoc.uva.es/handle/10324/70602
UL https://uvadoc.uva.es/handle/10324/70602
LA eng
NO Acta Neurologica Scandinavica, 2021, vol. 144, n. 4, p. 450-459
DS UVaDOC
RD 25-nov-2024